Saturday 17 October 2026 Export PRCT’s income statement to Excel — free account

PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024. In the quarter to June 2026, revenue grew 19.3%, EPS fell 34.3%, free cash flow fell 24.4% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

17.57 0.58 −3.20%

Follow PRCT

Alert me

Market cap: $1.0B
P/E: 0.0×
Fwd P/E: −18.2×
Dividend yield: —
F-score: 5/9
Altman Z: 6.44
Beneish M: −2.86
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 10.98

Total sells 0.62

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	—	—	—	1	—	—
Sell	—	—	—	—	6	—	—	3	—	—	3	—

Insider Ownership 4.29%

Capital & Financial Ratios $m

Market Cap 1,040.00

Revenue 337.34

Net Income (109.75)

Free Cash Flow (84.92)

Net Debt (176.20)

Current Ratio 6.55

Debt/Equity 0.15

P/E ratio 0.00

Fwd P/E (18.20)

P/S ratio 2.97

P/B ratio 2.95

Past 5Y EPS Growth —

This Y EPS Growth 2.77%

Next Y EPS Growth 31.13%

Next Y revenue growth 28.32%

Next 5Y EPS Growth 21.44%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.79%

10-year low 10-year high

P/B against its own 10 years 10.73%

10-year low 10-year high

EV/Sales against its own 10 years 3.16%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	257	334	287	228
Receivables	48	83	84	108
Inventory	40	56	71	77
Other	—	—	—	—
	351	482	450	420

	2023	2024	2025	Q'26
Payables	13	10	17	15
ST’ Debt	2	2	—	—
Other	6	8	10	12
	46	53	66	64

Compound Annual Growth %

	10y	5y	3y
Sales	—	109.04%	60.14%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	43.11%	22.90%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	83	94	—	—	—
’25	69	79	83	76	308
’24	45	53	58	68	224
’23	24	33	35	44	136
’22	14	17	20	24	75
’21	7	8	9	10	34
’20	—	—	2	—	8

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(38)	(19)	—	—	—
’25	(17)	(15)	(7)	(10)	(49)
’24	(32)	(16)	(19)	(32)	(99)
’23	(36)	(28)	(19)	(25)	(108)
’22	(18)	(17)	(20)	(25)	(80)
’21	(15)	(13)	(13)	(16)	(57)
’20	—	—	(35)	(13)	(48)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(41)	(22)	—	—	—
’25	(19)	(18)	(10)	(12)	(58)
’24	(34)	(17)	(19)	(34)	(104)
’23	(41)	(34)	(25)	(34)	(133)
’22	(18)	(17)	(21)	(26)	(83)
’21	(15)	(13)	(13)	(17)	(58)
’20	—	—	(35)	(13)	(49)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.56)	(0.47)	—	—	—
’25	(0.45)	(0.35)	(0.38)	(0.53)	(1.72)
’24	(0.51)	(0.50)	(0.40)	(0.35)	(1.75)
’23	(0.63)	(0.56)	(0.51)	(0.54)	(2.24)
’22	(0.39)	(0.43)	(0.51)	(0.63)	(1.96)
’21	(2.65)	(2.60)	(1.22)	(0.42)	(3.63)
’20	—	—	(2.77)	—	(14.47)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	24.20	15.38	24.83	39.48	27.80	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	47.73	52.40	43.90	103.81	89.49
People
People	Employees	—	—	—	—	205	234	428	626	756	888
	Revenue/emp, $m	—	—	—	0.00	0.04	0.15	0.18	0.22	0.30	0.35
Income, $m
Income, $m	Revenue	—	—	—	6	8	34	75	136	224	308
	Gross margin, %	—	—	—	(30.56)	(16.26)	46.02	49.44	52.17	61.07	63.70
	EBT	—	—	—	(42)	(53)	(60)	(87)	(106)	(91)	(95)
	EBT margin, %	—	—	—	(680.42)	(687.04)	(173.62)	(116.18)	(77.70)	(40.55)	(30.96)
	Net income	—	0	—	(42)	(53)	(60)	(87)	(106)	(91)	(96)
	Depreciation	—	—	—	1	3	3	3	4	5	6
Per share, $
Per share, $	Revenue	—	—	—	0.14	2.11	2.09	1.69	2.88	4.31	5.55
	Earnings	—	—	—	(0.97)	(14.47)	(3.63)	(1.96)	(2.24)	(1.75)	(1.72)
	Cash flow	—	—	—	(1.01)	(13.20)	(3.48)	(1.81)	(2.29)	(1.90)	(0.88)
	Capex	—	—	—	0.00	(0.06)	(0.04)	(0.06)	(0.53)	(0.08)	(0.17)
	Free cash flow	—	—	—	(1.01)	(13.26)	(3.51)	(1.87)	(2.82)	(1.99)	(1.05)
	Book value	—	—	—	0.68	16.64	16.21	4.44	5.94	7.72	6.59
	Shares, m	—	—	—	43	4	16	44	47	52	56
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.00	0.00	11.96	23.42	14.38	18.70	5.67
	P/B	—	—	—	0.00	0.00	1.54	8.91	6.98	10.43	4.78
	EV/Sales	—	—	—	0.00	0.00	4.68	21.18	12.88	17.45	4.92
	EV/FCF	—	—	—	(1.69)	(1.69)	(2.79)	(19.14)	(13.17)	(37.80)	(25.96)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(44)	(48)	(57)	(80)	(108)	(99)	(49)
	Capex	—	—	—	(8)	0	(1)	(3)	(25)	(4)	(9)
	Free cash flow	—	—	—	(44)	(49)	(58)	(83)	(133)	(104)	(58)
Balance, $m
Balance, $m	Working capital	—	—	—	44	96	310	237	305	429	385
	Total debt	—	—	—	23	52	54	55	53	53	52
	Net debt	—	—	—	(19)	(48)	(251)	(168)	(204)	(280)	(235)
	Shareholders’ equity	—	—	—	29	61	267	197	281	402	366
Returns, %
Returns, %	ROA	—	—	—	(135.41)	(56.41)	(25.85)	(26.97)	(29.66)	(19.48)	(18.34)
	ROIC	—	—	—	0.00	(225.01)	(206.72)	(170.70)	(88.89)	(49.51)	(49.56)
	ROE	—	—	—	25.69	32.45	(142.17)	(37.55)	(44.32)	(26.77)	(24.89)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TNDM Tandem Diabetes Care, Inc.	$1.2B	— (loss-making)	— (loss-making)	+5.77% (above 0%: growing)	n/m	−146.34% (below 0%: shrinking)	56.87%	(5.42%)	Compare
IRMD iRadimed Corporation	$1.1B	48.5×	48.7×	+0.28% (above 0%: growing)	−8.89% (below 0%: shrinking)	+11.66% (above 0%: growing)	74.07%	31.23%	Compare
ENOV Enovis Corporation	$1.1B	— (loss-making)	195×	+3.23% (above 0%: growing)	n/m	+815.79% (above 0%: growing)	61.64%	2.99%	Compare
AORT Artivion, Inc.	$1.1B	— (loss-making)	142×	+11.32% (above 0%: growing)	n/m	−202.47% (below 0%: shrinking)	64.03%	(6.65%)	Compare
CBLL CeriBell, Inc.	$1.1B	— (loss-making)	— (loss-making)	+32.54% (above 0%: growing)	n/m	−68.63% (below 0%: shrinking)	92.32%	(71.11%)	Compare
IART Integra LifeSciences Holdings Corporation	$1.1B	— (loss-making)	26.1×	+0.76% (above 0%: growing)	n/m	+193.48% (above 0%: growing)	52.47%	4.61%	Compare
PRCT PROCEPT BioRobotics Corporation	$1.0B	— (loss-making)	— (loss-making)	+19.34% (above 0%: growing)	n/m	−24.43% (below 0%: shrinking)	66.01%	(28.98%)
LMRI Lumexa Imaging Holdings, Inc.	$1.0B	— (loss-making)	14.2×	+7.82% (above 0%: growing)	n/m	+257.54% (above 0%: growing)	14.72%	8.72%	Compare
QDEL QuidelOrtho Corporation	$953.9M	— (loss-making)	— (loss-making)	+2.77% (above 0%: growing)	n/m	−61.45% (below 0%: shrinking)	43.26%	(3.46%)	Compare
Median of peers	$1.1B	—	48.7×	+4.50%	—	−24.90%	59.25%	(0.23%)

All 149 Medical Devices stocks →

PROCEPT BioRobotics Corporation (PRCT) key facts

Concern: PROCEPT BioRobotics Corporation reported a net loss of $95.6 million, or a loss of $1.72 per share, for fiscal 2025.
Strength: PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024.
PROCEPT BioRobotics Corporation (PRCT) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PRCT traded at $17.57, a market capitalization of $1.0 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 3.0× sales.
Return on equity was −24.9% and debt-to-equity 0.15.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 6.44 (safe zone) for fiscal 2025.